Find information on thousands of medical conditions and prescription drugs.

Floxuridine

Floxuridine is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colectoral cancer. more...

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

Floxuridine, an analog of 5-Fluorouracil, is a fluorinated pyrimidine.

Meachanism of action

Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.

History

Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the inotial work on 5-flurouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to Faulding, which became Mayne Pharma.

Suppliers

In the US the drug is supplied by Mayne Pharma as well as APP and Bedford.

Read more at Wikipedia.org


[List your site here Free!]


Hepatic arterial infusion
From Gale Encyclopedia of Cancer, by M.S. Crystal Heather Kaczkowski

Definition

Hepatic arterial infusion (HAI) therapy, delivers chemotherapeutic agents directly to the liver through a catheter placed in the hepatic artery. The hepatic artery is the main route of blood supply to liver tumors. HAI is also known as regional chemotherapy.

Purpose

Approximately 160,000 patients are diagnosed with colon cancer in the U.S. each year. The cancer spreads to the liver in about 70 percent of those patients. For patients with colorectal liver metastases, tumor progression within the liver is typically the primary cause of death.

Systemic chemotherapy using various agents has some efficacy, but the side effects can have a profound negative impact on the patient's quality of life during treatment. HAI therapy may be an effective option because it delivers chemotherapy medication directly to the site of the tumor, making it appropriate as an alternative or adjuvant treatment to systemic chemotherapy. When metastases is limited to the liver, HAI with floxuridine (FUDR) or radioactive microspheres through an implantable pump under the skin or an external pump worn on the belt may be a better option than systemic chemotherapy.

HAI may extend life expectancy and reduce the chance that more liver tumors will develop.

Precautions

  • Strict aseptic techniques should be used to prevent infection during all procedures.

  • Pump flow rate will vary depending on factors such as body temperature, altitude, arterial pressure at the catheter tip, and solution viscosity.

  • Patients should not attempt to resterilize the pump.

  • The manufacturer's instructions should be followed regarding drug preparation, dosage, and administration.

  • FUDR should be used with added caution in patients with impaired liver or kidney function.

Systemic therapy should be considered for patients with disease known to extend beyond the area capable of being infused.

Description

HAI enhances cancer therapy by increasing drug delivery directly to the site of the tumor (the liver) while minimizing systemic drug exposure and side effects. Development of fully implanted infusion systems have allowed for long-term delivery of hepatic regional chemotherapy.

  • yields higher tumor response rates and delays cancer progression

  • trend toward increased survival rates

  • enhances quality of life

  • reduced systemic side effects

      Benefits of HAI therapy:

      Preparation

      Patient selection criteria

      Successful results depend on careful patient selection.

    • have primary liver cancer or liver metastases from primary colorectal cancer

    • show an absence of tumors outside the liver

    • have demonstrated portal vein patency

    • be a suitable surgical candidate

    • show no evidence of infection

    • be willing to participate in frequent pump refill appointments

      Candidates for HAI therapy should:

      Studies have demonstrated that patients with metastatic colorectal cancer who had liver disease only, had less than 70% of their liver involved with metastases, and had a good performance status responded best to HAI. When metastases are also located outside of the liver, HAI does not offer an advantage over systemic chemotherapy.

      Aftercare

      During the course of treatment, pump pocket infections occur rarely. At the first sign of infection at the pump pocket, systemic antibiotics need to be started. The pump needs to be moved to a new location in a newly created pocket if the infection does not resolve itself. The old pocket should be opened and drained.

      Risks

      The major problems with HAI are not surgical. They include gastritis, duodenitis, and biliary sclerosis.

      Drug toxicity and medication side effects may occur. The most commonly reported side effects for FUDR are nausea and vomiting, diarrhea, and intestinal inflammation.

    • arterial thromboses

    • catheter dislodgement

    • the catheter may erode through the wall of the duodenum when the pump has been in place for more than a year.

    • overdose or underdose of medication if certain conditions affect the rate at which the pump delivers medication, i.e. pump damage due to strenuous activity, high heat, or a change in air pressure.

    • disruption in therapy if the pump is damaged by improper handling or filling.

      Other possible complications include:

      Normal results

      Morbidity or mortality occurring as a result of this procedure should be close to zero. Appropriate selection of patients and new combinations of chemotherapy should provide at least a 70% response rate from HAI for the treatment of hepatic metastases from colorectal primary tumors. This response rate is at least twice that of current systemic chemotherapies.

      When used in conjunction with traditional chemotherapy, HAI therapy has been shown to extend life expectancy and reduce recurrence of liver tumors after two years for certain patients.

      Abnormal results

    • infection

    • fluid build up around the implant site

    • skin erosion over the site of the implant

    • incision breakdown

    • drugs may be delivered to organs other than the liver

      Complications that can occur with surgery:

      KEY TERMS

      Adjuvant treatment
      A treatment that is added to increase effectiveness of the first treatment.

      Cancer
      A term for diseases in which abnormal cells divide without control. Cancer cells can invade nearby tissues and can spread through the bloodstream and lymphatic system to other parts of the body.

      Catheter
      A flexible tube used to administer or withdraw fluids. During a course of chemotherapy, an indwelling catheter can be placed in a vein to administer intravenous fluids and chemotherapy. Catheters can stay in place for several weeks or months with proper care.

      Chemotherapy
      A cancer treatment using medicines.

      Hepatic
      Refers to the liver.

      Implant
      A device inserted into the body to either treat cancer or to replace or substitute for a lost part or ability.

      Metastases
      The spread of cancer to other body parts.

      Tumor
      An abnormal mass of tissue that serves no purpose. Tumors may be either benign (non-cancerous) or malignant (cancerous).

      Return to Floxuridine
  • Home Contact Resources Exchange Links ebay